"Hermanos Ameijeiras" Surgical Clinical Hospital
Welcome,         Profile    Billing    Logout  
 9 Trials 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
García, Yolanda
MIRASOL, NCT04209855 / 2019-003509-80: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Calendar Jan 2023 - Jan 2023: From MIRASOL trial for high-grade epithelial ovarian cancer
Calendar Jul 2022 - Sep 2022: Approval for high-grade epithelial ovarian cancer (based on MIRASOL trial)
Checkmark Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
Checkmark [VIRTUAL] MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with hi.…
Recruiting
3
430
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
ImmunoGen, Inc., Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
12/22
04/24
ATOMICC, NCT03833479 / 2018-002155-15: TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Checkmark ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation.
Checkmark [VIRTUAL] Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study
Recruiting
2
132
Europe, RoW
No Further Treatment, TSR-042
Grupo Español de Investigación en Cáncer de Ovario, TESARO/GSK, Apices Soluciones S.L.
Cervical Cancer, Advanced Cancer
12/24
12/24
García, Jorge I
NCT03496766: Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Recruiting
2
18
Europe
Tipifarnib, Zarnestra
Spanish Lung Cancer Group
Non Small Cell Lung Cancer
01/23
10/23
Pérez, Mayte Lima
No trials found
Diéguez, Robin García
No trials found
Calvo, Vilma Fleites
No trials found
Ortiz, Jorge
No trials found
Suardiaz, María E
No trials found
Cascudo, Amarilis Grau
No trials found
Fleites, Ivelisse
No trials found
Domínguez, Carlos
No trials found
Gutiérrez, Angela
No trials found
Pérez, Mayté Lima
No trials found

Download Options